Sold to Horizon Pharma plc
Re-launched ACTIMMUNE® (interferon gamma-1b) in two ultra-orphan diseases, engaged with patient community, achieved 50%+ growth in new patients, and invested in new clinical research for other rare diseases.
Sold to Meda AB
Built gastroenterology, women’s health and OTC product portfolio through several acquisitions; innovative transaction structures enabled efficient capital structure.
IPO (later sold to Shionogi Pharma)
Led Sciele, formerly First Horizon, took company public through IPO, and built portfolio of specialty/hospital products through multiple acquisitions.
Sold to Valeant Pharmaceuticals
Led clinical development and regulatory submissions for Diastat, Migranal, and Retigabine in the neurology market.